Should Bacillus Calmette–Guérin (BCG) vaccine  be used in the prophylaxis of COVID-19?

Sanchez-Mostiero, Daisy O.; Melicor, Abigail F.

doi:10.47895/amp.v54i0.2566

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BCG vaccine has been getting attention for its possible immunomodulatory effects, primarily through the innate immune system, as prophylaxis for COVID-19. 221 Current evidence does not support this at present 222,223 but five clinical trials are underway among HCWs to determine the efficacy and safety of BCG vaccine in preventing COVID-19 and its severe symptoms. 223,224 Meanwhile, the US CDC has guidelines for prophylactic seasonal influenza vaccine use in long-term care facilities, and while the influenza vaccine is not effective against COVID-19 virus, it is highly recommended for vulnerable persons to get vaccinated each year to prevent seasonal influenza infection.…”

Section: There Is Insufficient Evidence For the Use Of The Bacillus C...mentioning

confidence: 99%

Otorhinolaryngology Out-Patient Practice in the “Post”-COVID-19 Era: Ensuring a Balance Between Service and Safety

Lapeña

Abes

Gomez

et al. 2020

Philipp J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Objective: To review available resources and provide evidence-based recommendations that may optimize otorhinolaryngologic out-patient health care delivery in the “post”-COVID-19 era while ensuring the safety of our patients, healthcare workers and staff. Data Sources: Relevant peer-reviewed journal articles; task force, organizational and institutional, government and non-government organization recommendations; published guidelines from medical, health-related, and scientific organizations. Methods: A comprehensive review of the literature on the COVID-19 pandemic as it pertained to “post”-COVID 19 out-patient otorhinolaryngologic practice was obtained from peer-reviewed articles, guidelines, recommendations, and statements that were identified through a structured search of the data sources for relevant literature utilizing MEDLINE (through PubMed and PubMed Central PMC), Google (and Google Scholar), HERDIN Plus, the World Health Organization (WHO) Global Health Library, and grey literature including social media (blogs, Twitter, LinkedIn, Facebook). In-patient management (including ORL surgical procedures such as tracheostomy) were excluded. Retrieved material was critically appraised and organized according to five discussion themes: physical office set-up, patient processing, personal protection, procedures, and prevention and health-promotion. Conclusion: These recommendations are consistent with the best available evidence to date, and are globally acceptable while being locally applicable. They address the concerns of otorhinolaryngologists and related specialists about resuming office practice during the “post”-COVID-19 period when strict quarantines are gradually lifted and a transition to the “new” normal is made despite the unavailability of a specific vaccine for SARS-CoV-2. While they target practice settings in the Philippines, they should be useful to ENT (ear, nose & throat) surgeons in other countries in ensuring a balance between service and safety as we continue to serve our patients during these challenging times. Keywords: COVID-19; SARS-CoV-2; otorhinolaryngology; otolaryngology head and neck surgery;ENT; out-patient practice; clinic practice.

show abstract

Section: There Is Insufficient Evidence For the Use Of The Bacillus C...mentioning

confidence: 99%

Otorhinolaryngology Out-Patient Practice in the “Post”-COVID-19 Era: Ensuring a Balance Between Service and Safety

Lapeña

Abes

Gomez

et al. 2020

Philipp J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

Role of Claudin- 3 as a biomarker of gut-skin axis integrity in patients with psoriasis

Mahran,

Hosni,

Farag

et al. 2024

Arch Dermatol Res

View full text Add to dashboard Cite

BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?

Koneru¹,

Batiha²,

Algammal³

et al. 2021

IDR

View full text Add to dashboard Cite

In late 2019, a new virulent coronavirus (CoV) emerged in Wuhan, China and was named as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This virus spread rapidly, causing the coronavirus disease-2019 (COVID-19) pandemic. Bacillus Calmette-Guérin (BCG) is a live attenuated tuberculosis (TB) vaccine, associated with induction of non-specific cross-protection against unrelated infections. This protection is a memory-like response in innate immune cells (trained immunity), which is caused by epigenetic reprogramming via histone modification in the regulatory elements of specific genes in monocytes. COVID-19 related epidemiological studies showed an inverse relationship between national BCG vaccination policies and COVID-19 incidence and death, suggesting that BCG may induce trained immunity that could confer some protection against SARS-CoV-2. As this pandemic has put most of Earth's population under quarantine, repurposing of the old, well-characterized BCG may ensure some protection against COVID-19. This review focuses on BCG-related cross-protection and acquisition of trained immunity, as well as the correlation between BCG vaccination and COVID-19 incidence and mortality.

show abstract

Should Bacillus Calmette–Guérin (BCG) vaccine be used in the prophylaxis of COVID-19?

Cited by 3 publications

References 0 publications

Otorhinolaryngology Out-Patient Practice in the “Post”-COVID-19 Era: Ensuring a Balance Between Service and Safety

Otorhinolaryngology Out-Patient Practice in the “Post”-COVID-19 Era: Ensuring a Balance Between Service and Safety

Role of Claudin- 3 as a biomarker of gut-skin axis integrity in patients with psoriasis

BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?

Contact Info

Product

Resources

About